Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
96 studies found for:    Medivation
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
2 Not yet recruiting A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Condition: Ovarian Cancer
Interventions: Drug: Talazoparib;   Drug: Temozolomide
3 Recruiting A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
Conditions: Prostate Carcinoma Metastatic to the Bone;   Castration Resistant Prostate Cancer
Intervention: Drug: Enzalutamide
4 Recruiting Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Conditions: Hormone Sensitive Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Leuprolide
5 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Conditions: Nonmetastatic Castration-Resistant Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo
6 Active, not recruiting Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MDV3100
7 Recruiting A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: talazoparib;   Drug: Physician's-Choice
8 Not yet recruiting Open-Label Extension and Safety Study of Talazoparib
Condition: Cancer
Intervention: Drug: Talazoparib
9 Approved for marketing A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Condition: Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone acetate;   Drug: prednisone
10 Active, not recruiting Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: exemestane;   Drug: Placebo (for enzalutamide)
11 Active, not recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
12 Active, not recruiting
Has Results
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Bicalutamide
13 Active, not recruiting Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Condition: Breast Cancer
Interventions: Drug: enzalutamide;   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant
14 Active, not recruiting Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: Talazoparib
15 Completed A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Dimebon;   Drug: Placebo
16 Active, not recruiting A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Conditions: Prostate Cancer;   Hormone Refractory Prostate Cancer
Intervention: Drug: MDV3100
17 Withdrawn Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Lymphoma, Large B-Cell, Diffuse;   Primary Mediastinal Large B-cell Lymphoma;   Transformed Indolent Lymphoma
Intervention: Biological: MDV9300
18 Active, not recruiting Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Abiraterone;   Drug: Placebo for Enzalutamide;   Drug: Prednisone
19 Active, not recruiting A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Intervention: Drug: talazoparib
20 Completed Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
Condition: Human Volunteers
Intervention: Drug: BMN 673

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.